Selective sensitivity to carboxyamidotriazole by human tumor cell lines with DNA mismatch repair deficiency

International Journal of Cancer

Volumn 123, Issue 2, 2008, Pages 258-263

  Yang, Jia Lin ^a,e   Qu, Xian Jun ^b   Yu, Yan ^a   Kohn, Elise C ^c   Friedlander, Michael L ^d  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b SHANDONG UNIVERSITY   (China)

^c NATIONAL CANCER INSTITUTE   (United States)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e PRINCE OF WALES HOSPITAL   (Australia)

Author keywords

Apoptosis; Calcium channel blocker; Cancer therapy; Carboxyamidotriazole; DNA mismatch repair

Indexed keywords

5 AMINO 1 [3,5 DICHLORO 4 (4 CHLOROBENZOYL)BENZYL] 1H 1,2,3 TRIAZOLE 4 CARBOXAMIDE; CALCIUM CHANNEL BLOCKING AGENT; FLUOROURACIL; NIFEDIPINE; PROTEIN MLH1; PROTEIN MSH6; ANTINEOPLASTIC AGENT; CARBOXYAMIDO TRIAZOLE; CARBOXYAMIDO-TRIAZOLE; TRIAZOLE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLADDER CARCINOMA; CANCER CELL; CANCER INHIBITION; CANCER INVASION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; COLON CARCINOMA; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG SENSITIVITY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MISMATCH REPAIR; OVARY CARCINOMA; PRIORITY JOURNAL; PROSTATE CARCINOMA; TUMOR CELL LINE; BLADDER TUMOR; CELL CYCLE; COLON TUMOR; COLORIMETRY; DRUG EFFECT; DRUG SCREENING; FEMALE; GENETIC TRANSFECTION; GENETICS; HUMAN CHROMOSOME; MALE; METHODOLOGY; NEOPLASM; OVARY TUMOR; PATHOLOGY; PROSTATE TUMOR;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CALCIUM CHANNEL BLOCKERS; CELL CYCLE; CELL LINE, TUMOR; CHROMOSOMES, HUMAN; COLONIC NEOPLASMS; COLORIMETRY; DNA MISMATCH REPAIR; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; FLUOROURACIL; HUMANS; MALE; NEOPLASM INVASIVENESS; NEOPLASMS; NIFEDIPINE; OVARIAN NEOPLASMS; PROSTATIC NEOPLASMS; TRANSFECTION; TRIAZOLES; URINARY BLADDER NEOPLASMS;

EID: 44949186460     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23535     Document Type: Article

References (33)

1. Gologan A, Sepulveda AR. Microsatellite instability and DNA mismatch repair deficiency testing in hereditary and sporadic gastrointestinal cancers. Clin Lab Med 2005;25:179-96.
2. Chai SM, Zeps N, Shearwood AM, Grieu F, Charles A, Harvey J, Goldblatt J, Joseph D, Iacopetta B. Screening for defective DNA mismatch repair in stage II and III colorectal cancer patients. Clin Gastroenterol Hepatol 2004;2:1017-25.
3. Coxhead JM, Williams EA, Mathers JC. DNA mismatch repair status may influence anti-neoplastic effects of butyrate. Biochem Soc Trans 2005;33:728-9.
4. Peltomaki P. Role of DNA mismatch repair defects in the pathogenesis of human cancer. J Clin Oncol 2003;21:1174-9.
5. Jacob S, Praz F. DNA mismatch repair defects: role in colorectal carcinogenesis. Biochimie 2002;84:27-47.
6. Palombo F, Gallinari P, Iaccarino I, Lettieri T, Hughes M, D'Amigo A, Truong O, Hsuan JJ, Jiricny J. GTBP, a 160-kilodalton protein essential for mismatch-binding activity in human cells. Science 1995;268:1912-4.
7. Bettstetter M, Dechant S, Ruemmele P, Grabowski M, Keller G, Holinski-Feder E, Hartmann A, Hofstaedter F. Distinction of hereditary nonpolyposis colorectal cancer and sporadic microsatellite-unstable colorectal cancer through quantification of MLH1 methylation by real-time PCR. Clin Cancer Res 2007;13:3221-8.
8. Fink D, Aebi S, Howell SB. The role of DNA mismatch repair in drug resistance. Clin Cancer Res 1998;4:1-6.
9. Carethers JM, Chauhan DP, Fink D, Nebel S, Bresalier RS, Howell SB, Boland CR. Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology 1999;117:123-31.
10. De Vos tot Nederveen Cappel WH, Meulenbeld HJ, Kleibeuker JH, Nagengast FM, Menko FH, Griffioen G, Gats A, Morreau H, Gelderblom H, Vasen HF. Survival after adjuvant 5-FU treatment for stage III colon cancer in hereditary nonpolyposis colorectal cancer. Int J Cancer 2004;109:468-71.
11. Yang JL, Friedlander ML. Effect of nifedipine in metastatic colon cancer with DNA mismatch repair gene defect. Lancet 2001;357:1767-8.
12. Kohn EC, Liotta LA. L651582: a novel antiproliferative and antimetastasis agent. J Natl Cancer Inst 1990;82:54-60.
13. Kohn EC, Felder CC, Jacobs W, Holmes KA, Day A, Freer R, Liotta LA. Structurefunction analysis of signal and growth-inhibition by carboxyamido-triazole, CAI. Cancer Res 1994;54:935-42.
14. Hupe DJ, Boltz R, Cohen CJ, Felix J, Ham E, Miller D, Soderman D, Van Skiver D. The inhibition of receptormediated and voltage-dependent calcium entry by the antiproliferative L-65 1582. J Biol Chem 1991;266:10136-42.
15. Kohn EC, Alessandro R, Spoonster J, Wersto RP, Liotta LA. Angiogenesis: role of calcium-mediated signal transduction. Proc Natl Acad Sci USA. 1994;92:1307-11.
16. Guo L, Li ZS, Wang HL, Ye CY, Zhang DC. Carboxyamido-triazole inhibits proliferation of human breast cancer cells via G(2)/M cell cycle arrest and apoptosis. Eur J Pharmacol 2006;24:538:15-22.
17. Perabo FG, Wirger A, Kamp S, Lindner H, Schmidt DH, Muller SC, Kohn EC. Carboxyamido-triazole (CAI), a signal transduction inhibitor induces growth inhibition and apoptosis in bladder cancer cells by modulation of Bcl-2. Anticancer Res 2004;24:2869-77.
18. Arnold CN, Goel A, Boland CR. Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines. Int J Cancer 2003;106:66-73.
19. O'Brien V, Brown R. Signalling cell cycle arrest and cell death through the MMR system. Carcinogenesis 2006;27:682-92.
20. Chao EC, Lipkin SM. Molecular models for the tissue specificity of DNA mismatch repair-deficient carcinogenesis. Nucleic Acids Res 2006;34:840-52.
21. Gong JG, Costanzo A, Yang HQ, Melino G, Kaelin WG Jr, Levrero M, Wang JY. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature 1999;399:806-9.
22. Zabkiewicz J, Clarke AR. DNA damage-induced apoptosis: insights from the mouse. Biochem Biophys Acta 2004;1705:17-25.
23. Muller A, Fishel R. Mismatch repair and the hereditary non-polyposis colorectal cancer syndrome (HNPCC). Cancer Invest 2002;30:102-9.
24. Hay T, Jenkins H, Sansom OJ, Martin NMB, Smith GCM, Clarke AR. Efficient deletion of normal Brca2-deficient intestinal epithelium by poly(ADP-Ribose) polymerase inhibition models potential prophylactic therapy. Cancer Res 2005;65:10145-8.
25. Alessandro R, Fontana S, Giordano M, Corrado C, Colomba P, Flugy AM, Santoro A, Kohn EC, DeLeo G. Effects of carboxyamidotriazole on in vitro models of imatinib-resistant chronic myeloid leukemia. J Cell Physiol 2008;215:111-21.
26. D'Amato M, Flugy AM, Alaimo G, Bauder B, Kohn EC, De Leo G, Alessandro R. Role of calcium in E-selectin induced phenotype of T84 colon carcinoma cells. Biochem Biophys Res Commun 2003;301:907-14.
27. Berlin J, Tutsch KD, Hutson P, Geary J, Rago RP, Azoomanian RZ, Alberti D, Feierabend C, Wilding G. Phase I clinical and pharmacokinetic study of oral carboxyamidotriazole, a signal transduction inhibitor. J Clin Oncol 1997;15:781-9.
28. Kohn EC, Figg WD, Sarosy GA, Bauer KS, Davis PA, Soltis MJ, Thompkins A, Liotta LA, Reed E. Phase I trial of micronized formulation carboxyamidotriazole in patients with refractory solid tumors: pharmacokinetics, clinical outcome, and comparison of formulations. J Clin Oncol 1997;15:1985-93.
29. Berlin J, Tutsch KD, Arzoomanian RZ, Alberti D, Binger K, Feierabend C, Dresen A, Mamocha R, Pluda J, Wilding G. Phase I and pharmacokinetic study of a micronized formulation of carboxyamidotriazole, a calcium signal transduction inhibitor: toxicity, bioavailability and the effect of food. Clin Cancer Res 2002;8:86-94.
30. Bauer KS, Figg WD, Hamilton JM, Jones EC, Premkumar A, Steinberg SM, Dyer V, Linehan WM, Pluda JM. A pharmacokinetically guided phase II study of CAI in androgen-independent prostate cancer. Clin Cancer Res 1999;5:2324-9.
31. Hussain MM, Kotz H, Minasian L, Premkumar A, Sarosy G, Reed E, Zhai S, Steinberg SM, Raggio M, Oliver VK, Figg WD, Kohn EC. Phase II trial of carboxyamidotriazole in patients with relapsed epithelial ovarian cancer. J Clin Oncol 2003;21:4356-63.
32. Dutcher JP, Leon L, Manola J, Friedland DM, Roth B, Wilding G, Eastern Cooperative Oncology Group. Phase II study of carboxyamidotriazole in patients with advanced renal cell carcinoma refractory to immunotherapy: E4896, an Eastern Cooperative Oncology Group Study. Cancer 2005;104:2392-9.
33. Stadler WM, Rosner G, Small E, Hollis D, Rini B, Zaentz SD, Mahoney J, Ratain MJ. Successful implementation of the randomized discontinuation trial design: an application to the study of the putative antiangiogenic agent carboxyaminoimidazole in renal cell carcinoma-CALGB 69901. J Clin Oncol 2005;23:3726-32.